Ogen 1.25

Low Testosterone, hypoestrogenism, moderate Vulvovaginal atrophy + 7 more

Treatment

13 FDA approvals

20 Active Studies for Ogen 1.25

What is Ogen 1.25

Estrone sulfate

The Generic name of this drug

Treatment Summary

Estrone sulfate (as estropipate) is a form of estrogen hormone replacement therapy that can be used to treat menopause symptoms, certain types of infertility, underdevelopment of female sexual characteristics, vaginal atrophy, certain types of breast cancer (especially in men and postmenopausal women), prostate cancer, and osteoporosis.

Ogen

is the brand name

image of different drug pills on a surface

Ogen 1.25 Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ogen

Estrone sulfate

1977

21

Approved as Treatment by the FDA

Estrone sulfate, also known as Ogen, is approved by the FDA for 13 uses including Hypogonadism and Postmenopausal Osteoporosis .

Hypogonadism

Postmenopausal Osteoporosis

Premature Ovarian Failure (POF)

Hot flashes

Premature Menopause

moderate Menopausal Vasomotor Symptoms

moderate Vulvovaginal atrophy

Low Testosterone

hypoestrogenism

Osteoporosis, Postmenopausal

Menopause

female castration

severe menopausal vulvovaginal atrophy

Effectiveness

How Ogen 1.25 Affects Patients

Estropipate is a type of estrogen, which is a hormone naturally produced by the body. Estropipate works by attaching to receptors that respond to estrogen in the body and helps to regulate the hormones LH and FSH. This can help to lower their levels in postmenopausal women.

How Ogen 1.25 works in the body

Estradiol is a hormone that acts on female organs, breasts, and other parts of the body. When it enters a cell, it binds to a receptor and enters the nucleus. This triggers the production of proteins that express the effects of estradiol on the cell. Estrogens also increase the production of certain proteins in the liver and decrease FSH production in the pituitary gland.

When to interrupt dosage

The proposed dosage of Ogen 1.25 is contingent upon the diagnosed circumstance, including Menopause, Menopause and hypoestrogenism. The quantity of dosage varies, in accordance with the delivery strategy (e.g. Oral or Tablet, coated) mentioned in the table below.

Condition

Dosage

Administration

female castration

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

Menopause

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

severe menopausal vulvovaginal atrophy

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

Low Testosterone

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

hypoestrogenism

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

moderate Vulvovaginal atrophy

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

Osteoporosis, Postmenopausal

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

Premature Menopause

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

moderate Menopausal Vasomotor Symptoms

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

Hot flashes

0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated

Warnings

There are 20 known major drug interactions with Ogen 1.25.

Common Ogen 1.25 Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Estrone sulfate.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Estrone sulfate.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Estrone sulfate.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Estrone sulfate.

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrone sulfate.

image of a doctor in a lab doing drug, clinical research

Ogen 1.25 Novel Uses: Which Conditions Have a Clinical Trial Featuring Ogen 1.25?

39 active clinical trials are presently investigating the potential of Ogen 1.25 in alleviating Low Testosterone, hypoestrogenism and moderate Menopausal Vasomotor Symptoms.

Condition

Clinical Trials

Trial Phases

female castration

0 Actively Recruiting

hypoestrogenism

1 Actively Recruiting

Phase 4

moderate Menopausal Vasomotor Symptoms

0 Actively Recruiting

moderate Vulvovaginal atrophy

0 Actively Recruiting

Premature Menopause

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Low Testosterone

6 Actively Recruiting

Phase 4, Phase 2, Phase 1

Menopause

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

severe menopausal vulvovaginal atrophy

0 Actively Recruiting

Ogen 1.25 Reviews: What are patients saying about Ogen 1.25?

5

Patient Review

4/12/2012

Ogen 1.25 for "Change of Life" Signs

I started taking ogen 5 years after my hysterectomy, when I was 34. I think this drug could really help a lot of women who are struggling emotionally and physically after surgery.

5

Patient Review

7/16/2010

Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries

I've been taking this drug for years with great results and no problems. I'm disappointed that it's no longer on the market. Can anyone explain why it was pulled?

5

Patient Review

6/10/2010

Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries

I loved that this medication had no side effects for me, but I'm disappointed that it's been taken off the market.

5

Patient Review

5/21/2009

Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries

I've been very pleased with the results of this treatment. I had surgery in 1990 and am wondering if I should continue taking it or not.

2

Patient Review

12/15/2009

Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries

I saw more success when I was taking this drug alongside estratest hs. Now that I've stopped, I'm back to experiencing extreme vaginal dryness and painful sex. Can I go back to alternating the estratest every other day and ogen every day? Is there something better out there?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ogen 1.25

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does OGEN do?

"Ogen (estropipate) tablets are a prescription medication used to treat the symptoms of menopause, ovarian failure, and the prevention of osteoporosis. Ogen may be used alone or with other medications and belongs to a class of drugs called estrogen derivatives. The safety and effectiveness of Ogen in children is not yet known."

Answered by AI

What does Premarin do to your body?

"Premarin is a type of hormone replacement therapy that helps to relieve the discomfort that many women feel during and after menopause. These symptoms include hot flashes, sweating, and vaginal dryness."

Answered by AI

What is OGEN made of?

"10, FD&C Blue No 1 and FD&C Red No. 3; OGEN. 750 (red tablet): FD&C Red No. 40, D&C Red 33,Yellow No. 6 and Red No. 3.

OGEN also contains colloidal silicon dioxide, dibasic potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and tromethamine. The color ingredients for the yellow tablet are: D&C Yellow No. 10, FD&C Blue No 1 and FD&C Red No. 3; The color ingredients for the red tablet are: FD&C Red No. 40, D&C Red 33,Yellow No. 6 and Red No. 3."

Answered by AI

Can you crush extended release tablets?

"There are some newer slow-release tablet formulations available that can be divided or halved."

Answered by AI

Clinical Trials for Ogen 1.25

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Alison B Hamilton, PhD MPH

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Have you considered Ogen 1.25 clinical trials?

We made a collection of clinical trials featuring Ogen 1.25, we think they might fit your search criteria.
Go to Trials
Image of Noll Laboratory in University Park, United States.

Estradiol and Elagolix for Menopause

42 - 64
Female
University Park, PA

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men. Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Phase 4
Recruiting

Noll Laboratory

W. Larry Kenney, Ph.D.

Have you considered Ogen 1.25 clinical trials?

We made a collection of clinical trials featuring Ogen 1.25, we think they might fit your search criteria.
Go to Trials
Image of Rehabilitation R&D Service, Baltimore, MD in Baltimore, United States.

Cognitive Behavioral Therapy for Menopause

18+
Female
Baltimore, MD

Women are the fastest-growing group of U.S. Veterans. Over half of those using VA care are 45 or older, with more age-related health concerns than civilian women. The VA urgently needs gender-informed strategies to ensure women Veterans receive tailored care that addresses their intersecting mental, physical, and age related health concerns, as well as gender-linked stressors. One prominent example is menopause, a health transition period that, for many women, can be associated with negative physical and mental health concerns that can worsen their functioning and quality of life. This project will: (1) integrate stakeholder feedback to tailor Cognitive Behavioral Therapy for Menopause (CBT-Meno) for women Veterans with menopause concerns; and (2) refine and evaluate tailored CBT-Meno as a treatment to address these intersecting needs in a clinical trial.

Waitlist Available
Has No Placebo

Rehabilitation R&D Service, Baltimore, MD (+2 Sites)

Haley Miles-McLean, PhD

Image of Student Health and Wellness Building - Department of Kinesiology in Charlottesville, United States.

Nitrate Supplementation and Exercise for Menopause

45 - 75
Female
Charlottesville, VA

Menopause greatly increases cardiovascular disease risk (CVD). Current exercise guidelines are inadequate to ameliorate this risk and higher intensity exercise may be necessary for cardiovascular benefits in postmenopausal females. Oral nitrate supplementation enhances exercise performance and CVD risk profile in several clinical conditions. The investigators recently reported that 3-days of nitrate supplementation in postmenopausal females enhances acute post-exercise vascular function, in an intensity dependent manner. The effects of nitrate supplementation and exercise training over a longer training program remains unexplored. This investigation will examine the impact of exercise training intensity with and without inorganic nitrate supplementation, on CVD and fitness outcomes. Postmenopausal females will be tested for maximal oxygen uptake and lactate threshold before randomization to one of four groups: that inorganic nitrate-rich beetroot juice, or beetroot juice with nitrate extracted; and assigned to one-month of calorie matched high-intensity or moderate-intensity exercise training. Vascular function and fitness will be evaluated before and after training.

Recruiting
Paid Trial

Student Health and Wellness Building - Department of Kinesiology

Jason Allen, PhD

Image of Neuromuscular Research Laboratory in Pittsburgh, United States.

Hormone Therapy for Musculoskeletal Health

18 - 40
All Sexes
Pittsburgh, PA

Non-combat-related muscle, tendon and bone injuries are the most common injuries suffered by military personnel, particularly in new recruits. These injuries impact military readiness and are responsible for roughly 60% of limited duty days, 65% of soldiers who are unable to deploy, and nearly $500 million in medical cost to the government annually in the Army alone. Drug interventions must be studied and developed to prevent these negative outcomes and prepare military personnel for the demands of military service. At the current time, military leadership has identified critical gaps in understanding how to minimize these injuries and train soldiers with drug intervention serving among those gaps. The goal of this study is to determine how a hormonal intervention can change muscle, tendon, and bone function as well as physical and psychological performance in response to mental and physical stress. To do so, we will examine sex hormone (testosterone, estrogen) levels, muscle, tendon, and bone images, blood samples, and physical and mental performance. We will look at things like changes in hormone levels, chemicals released from active skeletal muscles, and your body composition. The results from this study will be used to improve physical readiness training in the military with the goal of reducing injuries.

Phase 4
Recruiting

Neuromuscular Research Laboratory

Bradley C Nindl, PhD

Have you considered Ogen 1.25 clinical trials?

We made a collection of clinical trials featuring Ogen 1.25, we think they might fit your search criteria.
Go to Trials